Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

Elevra Lithium ( ($AU:ELV) ) has provided an update. Morella Corporation has significantly expanded the rubidium exploration footprint at its Mt Ed...

Morella Expands Rubidium Targets at Mt Edon After Strong Rock Chip Results

Elevra Lithium received a Buy rating and an A$8.60 price target from Macquarie analyst today. In addition to Macquarie, Elevra Lithium also receive...

Positive Report for Elevra Lithium (SYAXF) from Macquarie

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health, with a price target of $390.00. Acc...

Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX – Research Report) and Elevan...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Elevance Health (ELV)

In a report released yesterday, Reg Spencer from Canaccord Genuity maintained a Buy rating on Elevra Lithium, with a price target of A$14.50. The c...

Canaccord Genuity Keeps Their Buy Rating on Elevra Lithium (SYAXF)

Macquarie analyst maintained a Hold rating on Elevra Lithium today and set a price target of A$8.50. In addition to Macquarie, Elevra Lithium also ...

Macquarie Sticks to Their Hold Rating for Elevra Lithium (SYAXF)

Elevra Lithium ( ($AU:ELV) ) has provided an update. On January 23, 2026, Elevra Lithium Limited reported the lapse of 42,786 unlisted performance ...

Elevra Lithium Updates Market on Lapse of 42,786 Performance Rights

In a report released yesterday, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health. The company’s shares closed yes...

Truist Financial Reaffirms Their Buy Rating on Elevance Health (ELV)

Bernstein analyst Lance Wilkes maintained a Buy rating on Elevance Health today and set a price target of $431.00. According to TipRanks, Wilkes is...

Elevance Health (ELV) Receives a Buy from Bernstein

U.S. stocks finished the week mixed as gains in technology shares helped offset weakness in financial stocks and rising rate pressure. The Dow Jone...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 25

UnitedHealth ($UNH) is scheduled to release its fourth-quarter fiscal 2025 results before the market opens on January 27. Analysts expect the healt...

Is UnitedHealth Stock (UNH) a Buy Ahead of Q4 Earnings?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevance Health (ELV – Research Report) and Exelixis (EXEL – Rese...

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Exelixis (EXEL)

Elevra Lithium ( ($AU:ELV) ) just unveiled an announcement. On January 22, 2026, Elevra Lithium Limited filed a Form 6-K with the U.S. Securities a...

Elevra Lithium Expands Share Capital to Settle Piedmont Merger Equity Awards

Elevra Lithium ( ($AU:ELV) ) has issued an update. Elevra Lithium will release its December 2025 quarterly activities report on 28 January 2026 and...

Elevra Lithium Sets Date for Quarterly Results and Switches Reporting to USD

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. Elevra Lithium Limited has issued 372,486 new ordinary fully paid shares following the conver...

Elevra Lithium Issues 372,486 New Shares on Option Conversion

In a report released on January 16, Lance Wilkes from Bernstein maintained a Buy rating on Elevance Health, with a price target of $431.00. The com...

Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Macquarie analyst maintained a Buy rating on Elevra Lithium yesterday and set a price target of A$8.50. In a report released yesterday, Canaccord G...

Elevra Lithium (SYAXF) Gets a Buy from Macquarie

Elevra Lithium ( ($AU:ELV) ) just unveiled an announcement. Elevra Lithium has reworked its expansion plan for the North American Lithium mine, opt...

Elevra Fast-Tracks NAL Expansion With Staged Debottlenecking Plan

Elevra Lithium ( ($AU:ELV) ) has issued an announcement. Elevra Lithium will discontinue its sponsored OTCQB Venture Market listing at the close of...

Elevra Lithium to Drop Sponsored OTCQB Listing in Favour of Unsponsored OTC Quotation

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rubicon Organics (ROMJF – Research Report) and Enliv...

Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)

Enliven Therapeutics ( ($ELVN) ) just unveiled an announcement. On January 6, 2026, Enliven Therapeutics’ board appointed veteran biopharma executi...

Enliven Therapeutics appoints new board chair amid transition

In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Elevance Health, with a price target of $431.00. According to Ti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$335.74	-1.78%	789.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$335.74	-1.8%	789.90K
3
4
5
6

ELV

ELV

No Data Available

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel